Tuesday, February 12 17:21:09
Biotech multinational, Sanofi, today said it is to invest E44m in Genzyme's biotechnology campus in Waterford.
The investment will increase the site's diversity of products by adding the filling of Sanofi's Lantus (insulin glargine), the number one insulin brand worldwide.
Subject to regulatory approvals, commercial production of Lantus at Waterford should begin in 2016.
The investment is supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland.
Announcing the investment with Minister Bruton in Waterford, Dr. Martin Siewert, Vice President, Industrial Affairs, Pharmaceutical Injectables, Sanofi, said: "Since acquiring Genzyme almost two years ago, we have been continually impressed with the record of achievement at the Waterford site and with the positive and proactive approach taken by the site leadership. The entire Waterford team has shown great flexibility, professionalism and commitment, all valuable traits in a world-class manufacturing environment."
Dominic Carolan, Managing Director, Genzyme Ireland, said of the Sanofi announcement: "This represents a further major endorsement of the capability built up at the Waterford operation since 2001 and is evidence of Sanofi's commitment to the location and the confidence that exists in what Waterford can deliver. The team here should be proud of this achievement and their continued efforts."